Skip to main content

Main menu

  • Home
  • Current Issue
  • Ahead of Print
  • Past Issues
  • Info for
    • Authors
    • Print Subscriptions
  • About
    • About the Journal
    • About the Academy
    • Editorial Board
  • Feedback
  • Alerts
  • AAPL

User menu

  • Alerts

Search

  • Advanced search
Journal of the American Academy of Psychiatry and the Law
  • AAPL
  • Alerts
Journal of the American Academy of Psychiatry and the Law

Advanced Search

  • Home
  • Current Issue
  • Ahead of Print
  • Past Issues
  • Info for
    • Authors
    • Print Subscriptions
  • About
    • About the Journal
    • About the Academy
    • Editorial Board
  • Feedback
  • Alerts
LetterLetters

Letters

George Ide and Ahsan Khan
Journal of the American Academy of Psychiatry and the Law Online September 2021, 49 (3) 458; DOI: https://doi.org/10.29158/JAAPL.210070-21
George Ide
New York, NY
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahsan Khan
Lawton, OK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading
  • correctional psychiatry
  • drug formulary
  • informed consent

Editor:

Morris et al.,1 the authors of “Drug Formularies in Correctional Settings,” make a very persuasive argument for the standardization of drug formularies at U.S. correctional facilities. Morris et al.1 identify a critical topic of promoting uniformity and greater ease of access to pharmacotherapies for the prison population experiencing psychiatric illnesses.1 Although the U.S. Federal Bureau of Prisons Health Services National Formulary lists formulary/nonformulary medications commonly used in psychiatric care, each correctional facility has its own unique list.2 As the article explains, variations are attributed to site-specific drug policies, availability, and ease of laboratory services (such as phlebotomy) for monitoring, availability of licensed and trained personnel, and many other factors that ultimately dictate which drugs are available to a patient.1

As a correctional psychiatrist, one of us (AK) grapples with these challenges daily, particularly with transfer patients who cannot access the same medication they were prescribed at a previous correctional facility. When patients who were successfully treated with antidepressants such as bupropion at a previous facility can no longer access the same medication, a lot of unnecessary problems occur. It would therefore be more practical for patients and prescribers if the corrections department in each state followed the standardized formulary set by the Bureau of Prisons to match federal prisons. This would then encourage standardization in facilities operated by counties and municipalities, including juvenile detention centers. A standardized drug formulary is, however, far more effective if there are accompanying nonformulary protocols. The added transparency offers patients a better overall understanding of why certain medications are included, excluded, restricted, or unavailable, further encouraging informed consent.

While Morris et al.1 offer valuable recommendations for how to develop standardized drug formularies, we would like to take this opportunity to elucidate some other areas for improvement, such as the inclusion of atypical long-acting formulations for antipsychotic medications. Although second-generation antipsychotic medications are more expensive, they tend to decrease patient diversion and increase adherence, which is more cost-effective in the long run. Patients also report fewer side effects than with oral counterparts and benefit from a constant plasma level of the drug. These attributes aid patients in maintaining effective treatment once they re-enter society.

Morris et al.1 suggest a model formulary derived from a methodical process that incorporates input and collaboration from correctional prescribers, evidence-based rationale for the inclusion or exclusion of specific drugs, well-planned alternatives, and standardization among correctional facilities. We agree with all these recommendations and further suggest the Bureau of Prisons and all state correctional departments adopt a recurring schedule for updating standardized formularies and nonformulary protocols. Prescribers from correctional facilities should take part in making evidence-based recommendations founded on the effectiveness of commonly used psychiatric medications, cost-effective alternatives, new medications and generics, as well as the omission of drugs that have the potential for abuse and misdirection.

Footnotes

  • Disclosures of financial or other potential conflicts of interest: None.

  • © 2021 American Academy of Psychiatry and the Law

References

  1. 1.↵
    1. Morris NP,
    2. Hirschtritt ME,
    3. Tamburello AC
    : Drug formularies in correctional settings. J Am Acad Psychiatry Law 48:2–6, 2020
    OpenUrlFREE Full Text
  2. 2.↵
    Federal Bureau of Prisons Health Services: National Formulary Part I. Available at: https://www.bop.gov/resources/pdfs/2019_winter_national_formulary_part_I.pdf. Accessed May 7, 2021
PreviousNext
Back to top

In this issue

Journal of the American Academy of Psychiatry and the Law Online: 49 (3)
Journal of the American Academy of Psychiatry and the Law Online
Vol. 49, Issue 3
1 Sep 2021
  • Table of Contents
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in recommending The Journal of the American Academy of Psychiatry and the Law site.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Letters
(Your Name) has forwarded a page to you from Journal of the American Academy of Psychiatry and the Law
(Your Name) thought you would like to see this page from the Journal of the American Academy of Psychiatry and the Law web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Letters
George Ide, Ahsan Khan
Journal of the American Academy of Psychiatry and the Law Online Sep 2021, 49 (3) 458; DOI: 10.29158/JAAPL.210070-21

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Letters
George Ide, Ahsan Khan
Journal of the American Academy of Psychiatry and the Law Online Sep 2021, 49 (3) 458; DOI: 10.29158/JAAPL.210070-21
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Letters
  • Letters
Show more Letters

Similar Articles

Keywords

  • correctional psychiatry
  • drug formulary
  • informed consent

Site Navigation

  • Home
  • Current Issue
  • Ahead of Print
  • Archive
  • Information for Authors
  • About the Journal
  • Editorial Board
  • Feedback
  • Alerts

Other Resources

  • Academy Website
  • AAPL Meetings
  • AAPL Annual Review Course

Reviewers

  • Peer Reviewers

Other Publications

  • AAPL Practice Guidelines
  • AAPL Newsletter
  • AAPL Ethics Guidelines
  • AAPL Amicus Briefs
  • Landmark Cases

Customer Service

  • Cookie Policy
  • Reprints and Permissions
  • Order Physical Copy

Copyright © 2025 by The American Academy of Psychiatry and the Law